Watson and Natco sign a licensing deal for a generic Revlimid

12/7/2010 | Bloomberg Businessweek

Natco Pharma granted Watson Pharmaceuticals domestic development and marketing rights to lenalidomide, a generic version of Celgene's multiple myeloma treatment Revlimid. The agreement entitles Watson to a share of sales profit. Natco is expected to be the first company to file for approval of a generic Revlimid.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care